AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7408415 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (small doses)
Number of subjects: 8
Study 31495331 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous allogeneic mesenchymal stem cells (1.5 million cells/kg body weight)
Number of subjects: 36
Study 27723416 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (1 hour of yoga before dinner for 5 days)
Number of subjects: 38
Study 27723416 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 38
Study 25735605 — intervention group
Group type: EXPERIMENTAL
Intervention: Great Taste, Less Waste (GTLW) communications campaign
Number of subjects: 582
Study 25735605 — intervention group
Group type: EXPERIMENTAL
Intervention: Foods 2 Choose (F2C) nutrition-only campaign
Number of subjects: 582
Study 25735605 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 582
Study 23963894 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month hypocaloric diet (reduced carbohydrates or reduced fat content)
Number of subjects: 50
Study 21296325 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 509
Study 21296325 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical aortic valve replacement
Number of subjects: 509
Study 21296325 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon aortic valvuloplasty
Number of subjects: 509
Study 21296325 — intervention group
Group type: COMPARATOR
Intervention: Groups based on PASP levels
Number of subjects: 509
Study 19005465 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine 20 mg/day
Number of subjects: 138
Study 19005465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 17729010 — intervention group
Group type: EXPERIMENTAL
Intervention: Local intraarterial thrombolysis with recombinant tissue-type plasminogen activator (rtPA)
Number of subjects: 16
Study 17729010 — intervention group
Group type: COMPARATOR
Intervention: Intravenous anticoagulation using i.v. heparin infusion
Number of subjects: 16
Study 15132725 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 200 microg/day (low dose group)
Number of subjects: 101
Study 15132725 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 800 microg/day (high dose group)
Number of subjects: 101
Study 15132725 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 101
Study 11463679 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief psychodynamic interpersonal therapy
Number of subjects: 119
Study 11463679 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 119
Study 9875644 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1
Number of subjects: 24
Study 9875644 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 24
Study 7739439 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic added to sterile physiologic solution
Number of subjects: 33
Study 7739439 — intervention group
Group type: COMPARATOR
Intervention: Through drainage with sterile physiologic solution
Number of subjects: 33
Study 2918157 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem (0.25 mg/kg followed by 0.35 mg/kg body weight)
Number of subjects: 54
Study 2918157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 2918157 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem
Number of subjects: 54
Study 163386 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (1 gm three times a day for nine months, plus 3 gm daily at onset of cold)
Number of subjects: 311
Study 163386 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo (three times a day for nine months, plus placebo at onset of cold)
Number of subjects: 311
Study 163386 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Number of subjects: 311
Study 31175566 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational and training experiential intervention (ETEI)
Number of subjects: 25
Study 31175566 — intervention group
Group type: COMPARATOR
Intervention: Diet and nutrition education (Control)
Number of subjects: 25
Study 31152541 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU vitamin D3/d
Number of subjects: 273
Study 31152541 — intervention group
Group type: COMPARATOR
Intervention: 800 IU vitamin D3/d
Number of subjects: 273
Study 28376373 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation
Number of subjects: 0
Study 28376373 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 25936298 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml whipping cream (30% fat)
Number of subjects: 25
Study 25936298 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 g/kg l‐methionine
Number of subjects: 25
Study 23104183 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitatory scene priming (scene primes)
Number of subjects: 0
Study 23104183 — intervention group
Group type: COMPARATOR
Intervention: Control primes
Number of subjects: 0
Study 22071998 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula-driven transfusion protocol (1 plasma:1 platelet:1 RBC)
Number of subjects: 18
Study 22071998 — intervention group
Group type: COMPARATOR
Intervention: Laboratory-driven transfusion protocol
Number of subjects: 18
Study 19927632 — intervention group
Group type: EXPERIMENTAL
Intervention: TNK-tPA
Number of subjects: 110
Study 19927632 — intervention group
Group type: COMPARATOR
Intervention: rt-PA
Number of subjects: 110
Study 17509903 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide donation via a patch
Number of subjects: 3
Study 15350490 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with 3 million units (MU) of alpha‐interferon and 200 mg of ribavirin three times a week for 24 weeks.
Number of subjects: 20
Study 15350490 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with 3 million units (MU) of alpha‐interferon and 200 mg of ribavirin three times a week for 48 weeks.
Number of subjects: 20
Study 15350490 — intervention group
Group type: COMPARATOR
Intervention: Alpha‐interferon alone (historical data).
Number of subjects: 20
Study 11722315 — intervention group
Group type: EXPERIMENTAL
Intervention: Needs-based cognitive-behavioural family intervention plus general family support and standard care
Number of subjects: 79
Study 11722315 — intervention group
Group type: COMPARATOR
Intervention: General family support and standard care
Number of subjects: 79
Study 11722315 — intervention group
Group type: EXPERIMENTAL
Intervention: Needs-based cognitive-behavioural family intervention
Number of subjects: 79
Study 9738086 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (0.1 mg per kilogram)
Number of subjects: 518
Study 9738086 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital (15 mg per kilogram)
Number of subjects: 518
Study 9738086 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.15 mg per kilogram) followed by Phenytoin (18 mg per kilogram)
Number of subjects: 518
Study 9738086 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (18 mg per kilogram)
Number of subjects: 518
Study 9738086 — intervention group
Group type: COMPARATOR
Intervention: All treatments (Lorazepam, Phenobarbital, Diazepam plus Phenytoin, Phenytoin)
Number of subjects: 518
Study 8062154 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Number of subjects: 0
Study 8062154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8062154 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy age-matched premenopausal women
Number of subjects: 0
Study 2499830 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic, isosmotic lavage
Number of subjects: 0
Study 2499830 — intervention group
Group type: COMPARATOR
Intervention: Traditional three-day bowel preparation
Number of subjects: 0
Study 4834974 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbidopa plus 20% of previous levodopa dosage in fixed combination tablets (levodopa:carbidopa in a 10:1 ratio)
Number of subjects: 20
Study 4834974 — intervention group
Group type: COMPARATOR
Intervention: Levodopa alone
Number of subjects: 20
Study 4834974 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination tablets (levodopa:carbidopa in a 10:1 ratio)
Number of subjects: 20
Study 31107348 — intervention group
Group type: EXPERIMENTAL
Intervention: RPE (rating of perceived exertion)
Number of subjects: 82
Study 31107348 — intervention group
Group type: EXPERIMENTAL
Intervention: RM (repetition maximum)
Number of subjects: 82
Study 31107348 — intervention group
Group type: EXPERIMENTAL
Intervention: %1RM (percent one repetition maximum)
Number of subjects: 82
Study 31107348 — intervention group
Group type: EXPERIMENTAL
Intervention: RiR (repetitions in reserve)
Number of subjects: 82
Study 28279548 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements (ONS)
Number of subjects: 104
Study 28279548 — intervention group
Group type: COMPARATOR
Intervention: Dietary advice
Number of subjects: 104
Study 26829013 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing + Cognitive Behavioral Skills Training telephone counseling intervention
Number of subjects: 2151
Study 26829013 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 2151
Study 25120316 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg/d
Number of subjects: 175
Study 25120316 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg/d
Number of subjects: 175
Study 25120316 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 120 mg/d
Number of subjects: 175
Study 25120316 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg/d
Number of subjects: 175
Study 25120316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study 22417191 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Bereavement Program (FBP)
Number of subjects: 101
Study 22417191 — intervention group
Group type: COMPARATOR
Intervention: Literature control condition
Number of subjects: 101
Study 19464611 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh gas flow of 5 L/min
Number of subjects: 14
Study 19464611 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh gas flow of 10 L/min
Number of subjects: 14
Study 19464611 — intervention group
Group type: EXPERIMENTAL
Intervention: Flushing with O(2)
Number of subjects: 14
Study 19464611 — intervention group
Group type: EXPERIMENTAL
Intervention: Vital capacity breathing sessions
Number of subjects: 14
Study 19464611 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 14
Study 17485579 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 2114
Study 17485579 — intervention group
Group type: EXPERIMENTAL
Intervention: Implanted cardioverter-defibrillators (ICDs)
Number of subjects: 2114
Study 17485579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2114
Study 16239356 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin ER (500 mg once daily)
Number of subjects: 0
Study 16239356 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin IR (250 mg twice daily)
Number of subjects: 0
Study 16239356 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin ER
Number of subjects: 0
Study 16239356 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin IR
Number of subjects: 0
Study 16239356 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin ER and IR
Number of subjects: 0
Study 12219247 — intervention group
Group type: EXPERIMENTAL
Intervention: Slimming liposomes (SLC) containing esculoside, Centella asiatica extracts, caffeine, and L-carnitine
Number of subjects: 0
Study 12219247 — intervention group
Group type: EXPERIMENTAL
Intervention: Slimming liposomes (SLC)
Number of subjects: 0
Study 9568861 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound marking of the internal jugular vein before disinfection and local anaesthesia
Number of subjects: 65
Study 9568861 — intervention group
Group type: COMPARATOR
Intervention: Real-time ultrasound guidance during cannulation
Number of subjects: 65
Study 8749878 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin with low-dose betaxolol (20 mg once daily)
Number of subjects: 35
Study 8749878 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin with low-dose diltiazem (90 mg twice daily)
Number of subjects: 35
Study 8749878 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin with low-dose diltiazem and digoxin with low-dose betaxolol
Number of subjects: 35
Study 2667399 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg morphine
Number of subjects: 30
Study 2667399 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg morphine
Number of subjects: 30
Study 2667399 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 30
Study 1098671 — intervention group
Group type: EXPERIMENTAL
Intervention: Teoremac (420 mg/day for 14 days)
Number of subjects: 39
Study 1098671 — intervention group
Group type: COMPARATOR
Intervention: Indometacin (100 mg/day for 14 days)
Number of subjects: 39
Study 31366226 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray combined with a newly initiated oral antidepressant
Number of subjects: 0
Study 31366226 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant plus placebo
Number of subjects: 0
Study 28530448 — intervention group
Group type: EXPERIMENTAL
Intervention: Beef
Number of subjects: 24
Study 28530448 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey
Number of subjects: 24
Study 28530448 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate
Number of subjects: 24
Study 25381345 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupation-based approach using the iPad application, Aid for Decision-making in Occupation Choice.
Number of subjects: 54
Study 25381345 — intervention group
Group type: COMPARATOR
Intervention: Impairment-based approach focusing on patients' generic abilities and activities of daily living (ADL).
Number of subjects: 54
Study 23579211 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib (5 mg twice daily)
Number of subjects: 723
Study 23579211 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib (400 mg twice daily)
Number of subjects: 723
Study 23579211 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib
Number of subjects: 723
Study 23579211 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 723
Study 21364435 — intervention group
Group type: EXPERIMENTAL
Intervention: Obagi Nu‐Derm System
Number of subjects: 56
Study 21364435 — intervention group
Group type: COMPARATOR
Intervention: Standard care regimen
Number of subjects: 56
Study 19472699 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 48
Study 19472699 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 48
Study 16936557 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-9137 (200, 400, or 800 mg BID, 800 mg QD, or 50 mg+100 mg ritonavir QD)
Number of subjects: 40
Study 16936557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 14505546 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifid Triple Viable capsule (BIFICO), 420 mg/d
Number of subjects: 30
Study 14505546 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch)
Number of subjects: 30
Study 11533750 — intervention group
Group type: EXPERIMENTAL
Intervention: 200mg chromium/day as CrCL3
Number of subjects: 44
Study 9491672 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating immune complexes (CIC) estimated by polyethylene glycol precipitation (PEG pptn.) test and latex agglutination inhibition (LAI) test.
Number of subjects: 48
Study 9491672 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage I genitourinary cancer patients
Number of subjects: 48
Study 9491672 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage II genitourinary cancer patients
Number of subjects: 48
Study 9491672 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage III genitourinary cancer patients
Number of subjects: 48
Study 9491672 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage IV genitourinary cancer patients
Number of subjects: 48
Study 8238131 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labor
Number of subjects: 93
Study 8238131 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 93
Study 3911373 — intervention group
Group type: EXPERIMENTAL
Intervention: VBCMP
Number of subjects: 96
Study 3911373 — intervention group
Group type: COMPARATOR
Intervention: VMP
Number of subjects: 96
Study 3911373 — intervention group
Group type: COMPARATOR
Intervention: MP
Number of subjects: 96
Study 29437758 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 1030
Study 29437758 — intervention group
Group type: COMPARATOR
Intervention: Control (questionnaire only)
Number of subjects: 1030
Study 26965429 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized e-therapy program in addition to usual care
Number of subjects: 120
Study 26965429 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control group)
Number of subjects: 120
Study 23764858 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle strength training (IMST) 5 days/week at the highest tolerated load
Number of subjects: 16
Study 23764858 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle strength training (IMST)
Number of subjects: 16
Study 23684832 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG revaccination
Number of subjects: 0
Study 23684832 — intervention group
Group type: COMPARATOR
Intervention: Control group (lower or null increase of IFN-γ)
Number of subjects: 0
Study 20947595 — intervention group
Group type: EXPERIMENTAL
Intervention: Bypass grafting plus transplantation of bone marrow‐derived stem cells
Number of subjects: 34
Study 20947595 — intervention group
Group type: COMPARATOR
Intervention: Revascularization only (control group)
Number of subjects: 34
Study 17981067 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPw‐HBV/Hib‐MenAC vaccine (2.5 microg of each polysaccharide, 5 microg of each polysaccharide, or 2.5 microg of PRP and 5 microg each of MenA and MenC)
Number of subjects: 0
Study 17981067 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPw‐HBV/Hib‐MenAC vaccine
Number of subjects: 0
Study 17981067 — intervention group
Group type: COMPARATOR
Intervention: Licensed DTPw‐HBV and Hib or DTPw‐HBV/Hib and MenC conjugate vaccines
Number of subjects: 0
Study 16148455 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (1.8% and 3.6%)
Number of subjects: 23
Study 16148455 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no active cannabinoids)
Number of subjects: 23
Study 16148455 — intervention group
Group type: EXPERIMENTAL
Intervention: THC with varying concentrations of CBC (0.1% versus 0.5%) and CBD (0.2% versus 1.0%)
Number of subjects: 23
Study 12942093 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated TBI (fTBI)
Number of subjects: 180
Study 12942093 — intervention group
Group type: COMPARATOR
Intervention: Total Body Irradiation (TBI)
Number of subjects: 180
Study 12942093 — intervention group
Group type: COMPARATOR
Intervention: Busulphan
Number of subjects: 180
Study 12942093 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete T cell donor chimerism
Number of subjects: 180
Study 12942093 — intervention group
Group type: EXPERIMENTAL
Intervention: T cell mixed chimerism (MC)
Number of subjects: 180
Study 10751812 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium (0.1 mg kg(‐1))
Number of subjects: 20
Study 10751812 — intervention group
Group type: COMPARATOR
Intervention: Pipecuronium (0.07 mg kg(‐1))
Number of subjects: 20
Study 8835586 — intervention group
Group type: EXPERIMENTAL
Intervention: ICRC vaccine
Number of subjects: 368
Study 8835586 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 368
Study 1388120 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin plus ciprofloxacin
Number of subjects: 80
Study 1388120 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin plus piperacillin
Number of subjects: 80
Study 3965341 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A therapy, 50,000 U twice daily
Number of subjects: 86
Study 3965341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 29534741 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive mental health care program
Number of subjects: 0
Study 29534741 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary team intervention
Number of subjects: 0
Study 27530379 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-05280586
Number of subjects: 214
Study 27530379 — intervention group
Group type: COMPARATOR
Intervention: rituximab-EU
Number of subjects: 214
Study 27530379 — intervention group
Group type: COMPARATOR
Intervention: rituximab-US
Number of subjects: 214
Study 24703319 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 211
Study 24703319 — intervention group
Group type: COMPARATOR
Intervention: Non-bevacizumab treatment
Number of subjects: 211
Study 24703319 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab with high tissue mRNA of angiogenic VEGF‐Axxxa
Number of subjects: 211
Study 22522185 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaning forward (associated with heightened urge to approach stimuli)
Number of subjects: 0
Study 22522185 — intervention group
Group type: COMPARATOR
Intervention: Reclining (associated with less of an urge to approach stimuli)
Number of subjects: 0
Study 22522185 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaning forward
Number of subjects: 0
Study 22522185 — intervention group
Group type: COMPARATOR
Intervention: Reclining
Number of subjects: 0
Study 20453572 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment Education Program (EEP)
Number of subjects: 48
Study 17964402 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%
Number of subjects: 185
Study 17964402 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 185
Study 17964402 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 mg
Number of subjects: 185
Study 17964402 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral acetylcholine
Number of subjects: 185